Joseph Catanzaro
Stock Analyst at Piper Sandler
(3.56)
# 795
Out of 5,179 analysts
108
Total ratings
45.56%
Success rate
6.79%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $12 | $4.52 | +165.49% | 7 | Mar 23, 2026 | |
| ERAS Erasca | Maintains: Outperform | $16 → $19 | $14.97 | +26.92% | 1 | Mar 13, 2026 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $19 → $20 | $19.26 | +3.84% | 3 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $9.81 | +165.04% | 1 | Mar 2, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $14.76 | +137.13% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $7.38 | -5.15% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $92.51 | +54.58% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $13.89 | +180.78% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $8.67 | +488.24% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $18.37 | -2.01% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $53 | $47.31 | +12.03% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $78.16 | +53.53% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $30.30 | +58.42% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $105 | $77.82 | +34.93% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $3.51 | +70.94% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $11.08 | +306.14% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $134.25 | -18.06% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $41.53 | -8.50% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $10.61 | +41.38% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $61.63 | -14.00% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.55 | +545.16% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.32 | +1,339.39% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $9.37 | +102.77% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.03 | +638.92% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $8.40 | +328.57% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $21.41 | +86.83% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.55 | +98.68% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.59 | +73.75% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.33 | +2,155.64% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.10 | +1,714.88% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.75 | -36.36% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.40 | -14.53% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $3.45 | -56.52% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $27.68 | +622.54% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $14.70 | +138.10% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.30 | +4,515.38% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.27 | +692.95% | 3 | Apr 7, 2020 |
CytomX Therapeutics
Mar 23, 2026
Maintains: Overweight
Price Target: $10 → $12
Current: $4.52
Upside: +165.49%
Erasca
Mar 13, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $14.97
Upside: +26.92%
Tango Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $19 → $20
Current: $19.26
Upside: +3.84%
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $9.81
Upside: +165.04%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $14.76
Upside: +137.13%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $7.38
Upside: -5.15%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $92.51
Upside: +54.58%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $13.89
Upside: +180.78%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $8.67
Upside: +488.24%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $18.37
Upside: -2.01%
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $47.31
Upside: +12.03%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $78.16
Upside: +53.53%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $30.30
Upside: +58.42%
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $77.82
Upside: +34.93%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.51
Upside: +70.94%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $11.08
Upside: +306.14%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $134.25
Upside: -18.06%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $41.53
Upside: -8.50%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $10.61
Upside: +41.38%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $61.63
Upside: -14.00%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.55
Upside: +545.16%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.32
Upside: +1,339.39%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $9.37
Upside: +102.77%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.03
Upside: +638.92%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $8.40
Upside: +328.57%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $21.41
Upside: +86.83%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $7.55
Upside: +98.68%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.59
Upside: +73.75%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.33
Upside: +2,155.64%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.10
Upside: +1,714.88%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.75
Upside: -36.36%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.40
Upside: -14.53%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $3.45
Upside: -56.52%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $27.68
Upside: +622.54%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $14.70
Upside: +138.10%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.30
Upside: +4,515.38%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.27
Upside: +692.95%